Company intelligence / Profile preview

Innovecs

Ownership: Private
Development stage: Other

Overview

InnoVec has received FDA clearance of its IND application for IVB103, an AAV-based gene therapy targeting nAMD. The company’s custom capsid technology enables intravitreal administration with improved safety and efficacy profiles. Preclinical data support the advancement of additional programs in ocular and neuromuscular diseases.

Therapeutic areas: OphthalmologyNeurology
Modalities: Gene therapyAdeno-associated virus (AAV)-based gene therapyViral vector-based gene therapyNucleic acid delivery carrier (fully human-derived viral vectors)
Industry: Biotech

Partnerships

uBriGene Biosciences (CDMO partner)Cyagen Biosciences

Beyond the preview

Go deeper on Innovecs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovecs.

Explore the full profile